AposHealth

Company Overview

Snapshot

Founded in January 2004, AposHealth operates with 51–200 employees. The company has raised $37 million across 5 funding rounds from 5 investors. In February 2020, AposHealth announced an $11 million Series A extension funding round.

Business overview

AposHealth develops solutions for identifying and treating gait-related conditions within the Health Tech & Life Sciences sector. Its core product, the Apos3 device, is FDA-cleared for knee osteoarthritis treatment, aiming to reduce pain and improve lower extremity function. Additionally, it serves as a non-FDA-cleared wellness device for other gait-related issues like chronic low back and hip pain. Through its AposIQ business unit, the company leverages innovative technology and data science to optimize gait adjustments, serving markets in the United Kingdom, United States, and Singapore.

Strategic signal

In May 2020, research published in The Journal of the American Medical Association (JAMA) highlighted that knee osteoarthritis patients treated with AposTherapy experienced significant pain reduction. This publication provides strong clinical validation for AposHealth's technology, reinforcing its efficacy and potentially expanding its adoption among healthcare providers and patients seeking non-surgical solutions for chronic pain.

Company Intelligence Q&A

What was the most recent funding event for AposHealth?

In February 2020, AposHealth announced an $11 million Series A extension funding round, with aMoon Fund participating.

What is the primary focus of AposHealth's product development?

AposHealth focuses on developing solutions for the identification and treatment of gait-related conditions, including knee osteoarthritis, chronic low back, and hip pain.

What was a key partnership announced by AposTherapy in March 2020?

In March 2020, AposTherapy partnered with three physical therapy providers in Queens, New York, to offer its non-surgical solution for knee and lower back pain sufferers.

Which publication featured research on AposTherapy's effectiveness?

In May 2020, research published in The Journal of the American Medical Association (JAMA) showed that knee osteoarthritis patients treated with AposTherapy experienced significant pain reduction.

What was a significant development regarding insurance coverage for AposTherapy in New York?

In August 2020, Healthfirst New York formalized coverage of AposTherapy, an innovative therapy designed for orthopedic conditions.